Entelos will use Compaq high-throughput simulation and virtual lab for testing of new drug therapies

Entelos develops large-scale mathematical models of complex, chronic diseases. Researchers use the virtual experimentation environment of the PhysioLab to rapidly simulate experiments on a computer, using virtual patients, targets and therapies that otherwise, could take months or years to accomplish in the laboratory or clinic. Pharmaceutical companies use this information to identify novel pathways, prioritize drug targets and candidates, optimize experiments and clinical trials, understand variable patient responses to treatment, and increase productivity throughout the drug development pipeline. Entelos currently has eight major pharmaceutical customers and PhysioLab systems in asthma, obesity and diabetes.

Compaq AlphaServer systems running Tru64 UNIX were selected to provide the high performance computing capability for Entelos' systems biology approach. The computing power of the AlphaServers will empower Entelos to further accelerate drug discovery, drug development, and disease research. In the future, Compaq and Entelos will work closely together as Compaq transfers key enterprise-class Alpha processor technology, tools and resources to the Intel Itanium processor family architecture, ensuring continued advantage of Compaq high-performance enterprise technology.